Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Objective Response Rate”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT04698785
What this trial is testing

Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients

Who this might be right for
Bone SarcomaOsteosarcoma
Centre Leon Berard 36
Testing effectiveness (Phase 2)WithdrawnNCT02014831
What this trial is testing

Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)

Who this might be right for
Squamous Cell Carcinoma of the Penis
Centre Leon Berard
Large-scale testing (Phase 3)Not Yet RecruitingNCT07346053
What this trial is testing

The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer

Who this might be right for
Advanced Bladder Cancer
Guliz Ozgun 224
Testing effectiveness (Phase 2)Study completedNCT02366195
What this trial is testing

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

Who this might be right for
Unresected Stage IIIb to IVM1c Melanoma
Amgen 112
Large-scale testing (Phase 3)UnknownNCT04741438
What this trial is testing

Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

Who this might be right for
Sarcoma
Centre Leon Berard 96
Testing effectiveness (Phase 2)Looking for participantsNCT07150247
What this trial is testing

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

Who this might be right for
BRAF V600 Colorectal Cancer
Sun Yat-sen University 20
Not applicableStudy completedNCT02453425
What this trial is testing

The Effects of Blood Pressure on Renal Function and Oxygenation in Septic Shock

Who this might be right for
Septic ShockAcute Kidney Injury
Sahlgrenska University Hospital 8
Testing effectiveness (Phase 2)UnknownNCT05310383
What this trial is testing

Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

Who this might be right for
Recurrent Cervical CarcinomaMetastatic Cervical CarcinomaPersistent Cervical Carcinoma+7 more
Lei Li 58
Testing effectiveness (Phase 2)Looking for participantsNCT07793695
What this trial is testing

Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Anhui Provincial Hospital 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07683507
What this trial is testing

Becotatug Vedotin Plus PD-1 Inhibitor for Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Feng Liu 60
Testing effectiveness (Phase 2)Looking for participantsNCT07320508
What this trial is testing

Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study

Who this might be right for
Adenoid Cystic CarcinomaSinonasal CarcinomaEpirubicin
Eye & ENT Hospital of Fudan University 100
Testing effectiveness (Phase 2)Looking for participantsNCT05257018
What this trial is testing

R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

Who this might be right for
Diffuse Large B-cell Lymphoma
Fudan University 83
Testing effectiveness (Phase 2)Ended earlyNCT00620100
What this trial is testing

To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent

Who this might be right for
Breast Neoplasms
Sanofi 2
Testing effectiveness (Phase 2)Study completedNCT01915589
What this trial is testing

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

Who this might be right for
Carcinoma, Hepatocellular
Bayer 16
Early research (Phase 1)Study completedNCT00481728
What this trial is testing

Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.

Who this might be right for
Overactive Bladder
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 28
Testing effectiveness (Phase 2)UnknownNCT04635956
What this trial is testing

Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Who this might be right for
ChemotherapyAnti-pd-1 AntibodyCervical Neuroendocrine Carcinoma+4 more
Lei Li 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07145931
What this trial is testing

Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base

Who this might be right for
Head and Neck Cancer Squamous Cell CarcinomaSkull Base--CancerNeoadjuvant Chemoimmunotherapy+1 more
Sun Yat-sen University 24
Testing effectiveness (Phase 2)UnknownNCT01192230
What this trial is testing

Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Fudan University 30
Very early researchEnrolling By InvitationNCT07356466
What this trial is testing

Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric (Stomach) Cancer
Fujian Medical University 100
Not applicableUnknownNCT03336554
What this trial is testing

Epigenetic Biomarker for Osteosarcoma

Who this might be right for
Histologic Response (Tumor Necrosis Rate)Objective Response Rate for Neoadjuvant Chemotherapy, ORRProgression-free Survival, PFS+1 more
Peking University People's Hospital 100
Next Page